Biomarker Commons

MET protein levels correlate strongly with epithelial-mesenchymal transition (EMT) phenotype, a treatment-resistant type of colorectal cancer and may be used as a surrogate biomarker, according to new research from The University of Texas MD Anderson Cancer Center.

The study results, which compared MET protein expression with protein/gene expression of EMT markers and evaluated impact on survival, were released recently at the annual meeting of the American Society of Clinical Oncology.

bioTheranostics, Inc., a leading provider of molecular diagnostic solutions for cancer, recently announced that 11 data presentations will be released during the American Society of Clinical Oncology (ASCO) annual meeting May 31–June 4, 2013, in Chicago. The studies highlight the clinical utility of the company’s CancerTYPE ID® assay and Breast Cancer IndexSM (BCI), with results supporting the role of these molecular tests in individualized treatment programs for cancer patients.

Genomic Health, Inc. (Nasdaq: GHDX) recently announced results of 10 studies being presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, underscoring the company's commitment to optimizing cancer treatment.  New data include studies of the Oncotype DX® RT-PCR-based breast, colon and prostate cancer tests and a large next generation sequencing (NGS) study that reports novel methods for detection of gene fusions to enhance the understanding of breast cancer tumor biology for future clinical developments.

Entelos Holding Corp. (“Entelos” or “the Company”), a premier provider of physiologicalsystemmodeling and services, and Seattle-based Institute for System Biology (ISB), the nonprofit pioneers of the systems approach to study the molecular causes of diseases, today announced the successful integration of gene expression data into quantitative physiological simulations.